Syros Pharmaceuticals, Inc.
SYRS · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 27.7% |
| R&D Expenses | $21 | $22 | $24 | $21 |
| G&A Expenses | $6 | $5 | $6 | $6 |
| SG&A Expenses | $6 | $5 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26 | $27 | $31 | $27 |
| Operating Income | -$26 | -$27 | -$31 | -$27 |
| % Margin | – | – | – | -6,996.1% |
| Other Income/Exp. Net | $20 | $4 | $27 | -$37 |
| Pre-Tax Income | -$6 | -$23 | -$4 | -$64 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$6 | -$23 | -$4 | -$64 |
| % Margin | – | – | – | -16,679.8% |
| EPS | -0.16 | -0.59 | -0.095 | -2.18 |
| % Growth | 72.9% | -520.4% | 95.6% | – |
| EPS Diluted | -0.16 | -0.59 | -0.095 | -2.18 |
| Weighted Avg Shares Out | 39 | 39 | 39 | 30 |
| Weighted Avg Shares Out Dil | 39 | 39 | 39 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $2 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$22 | -$2 | -$63 |
| % Margin | – | – | – | -16,263.2% |